Adjuvant tebentafusp (IMCgp100) versus observation in HLA-A*0201 positive patients with high-risk non-metastatic uveal melanoma: an EORTC randomized phase III study (ATOM Trial)
Phase: Phase III clinical trials
Principal Investigator: Dott. Del Vecchio Michele
Main Facility: Oncologia Medica 1 - Unità Oncologia Medica Melanomi
Drug: Tebentafusp (IMCgp100)
Pathologies: Melanoma
ClinicalTrials.gov: Read the details about clinical trials
The ATOM study is a global Phase 3 clinical trial in patients with high-risk non-metastatic uveal melanoma who are HLA-A*02:01 positive. The study is designed to evaluate the safety and efficacy of tebentafusp, a novel immunotherapy administered as adjuvant treatment following definitive treatment of the primary tumor (surgery or radiotherapy), compared with observation alone, which represents the current standard of care in this setting.
Participants will be randomly assigned (1:1 randomization) to one of two treatment arms in order to compare the investigational treatment with the current standard management approach.
Arm A (Investigational Arm): tebentafusp administered intravenously, an immunotherapeutic agent designed to activate the immune system to recognize and eliminate uveal melanoma cells.
Arm B (Control Arm): clinical observation without adjuvant drug treatment, which represents the current standard of care.
The objective of the study is to determine whether adjuvant treatment with tebentafusp can reduce the risk of disease recurrence and improve survival compared with observation alone.
Last update: 14/07/2026